Estimation of Baseline Dopamine D2 Receptor Occupancy in Striatum and Extrastriatal Regions in Humans with Positron Emission Tomography with [18F] Fallypride

Biological Psychiatry

Volumn 63, Issue 2, 2008, Pages 241-244

  Riccardi, Patrizia ^a   Baldwin, Ron ^a   Salomon, Ronald ^a   Anderson, Sharlet ^a   Ansari, Mohammad S ^a   Li, Rui ^a,b   Dawant, Benoit ^b   Bauernfeind, Amy ^a   Schmidt, Dennis ^a   Kessler, Robert ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

methyl para tyrosine (AMPT) challenge; 18F fallypride; dopamine; dopamine D2 receptors; humans; PET

Indexed keywords

DOPAMINE 2 RECEPTOR; FALLYPRIDE F 18; METIROSINE; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; SUBSTANTIA NIGRA; THALAMUS;

ADULT; BENZAMIDES; BRAIN MAPPING; CORPUS STRIATUM; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2;

EID: 37349114846     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.03.022     Document Type: Article

References (34)

1. Laruelle M., D'Souza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17 (1997) 162-174
2. Verhoeff N.P., Kapur S., Hussey D., Lee M., Christensen B., et al. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25 (2001) 213-223 C Psych
3. Verhoeff N.P., Hussey D., Lee M., Tauscher J., Papatheodorou G., Wilson A.A., et al. Dopamine depletion results in increased neostriatal D (2), but not D (1), receptor binding in humans. Mol Psychiatry (2002) 322-328 7:233
4. Kegeles L.S., Mawlawi O., Rodenhiser J., Martinez D., Broft A., Fullerton C., et al. Measurement of the D2 receptor occupancy by dopamine in human ventral and dorsal striatum. J Nucl Med 42 (2001) 16P
5. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000) 8104-8109
6. Seeman P., and Kapur S. Schizophrenia: More dopamine, more D2 receptors. Proc Natl Acad Sci U S A 97 (2000) 7673-7675
7. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50 (2001) 825-844
8. Kerwin R.W., and Murray R.M. A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia. Schizophr Res 7 (1992) 1-12
9. Goldman-Rakic P.S. The cortical dopamine system: Role in memory and cognition. Adv Pharmacol 42 (1998) 707-711
10. Yasuno F., Suhara T., Okubo Y., Sudo Y., Inoue M., Ichimiya T., et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161 (2004) 1016-1022
11. Mukherjee J., Yang Z.Y., Lew R., Brown T., Kronmal S., Cooper M.D., and Seiden L.S. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. Synapse 27 (1997) 1-13
12. Slifstein M., Narendran R., Hwang D.R., Sudo Y., Talbot P.S., Huang Y., and Laruelle M. Effect of amphetamine on [(18)F] fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54 (2004) 46-63
13. Riccardi P., Li R., Ansari M.S., Zald D., Park S., Dawant B., et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31 (2006) 1016-1026
14. Pluim J.P.W., Maintz J.B.A., and Viergever M.A. Mutual information matching in multiresolution context. Image and Vision Computing 19 (2001) 45-52
15. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., and Meltzer H.Y. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31 (2006) 1991-2001
16. Lammertsma A.A., Bench C.J., Hume S.P., Osman S., Gunn K., Brooks D.J., and Frackowiak R.S. Comparison of methods for analysis of clinical [11C] raclopride studies. J Cereb Blood Flow Metab 16 (1996) 42-52
17. 18F] N-allyl-5- fluoroprorlepidepride (fallypride): Radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. NeuroImage 11 (2000) S32
18. Grunder G., Landvogt C., Vernaleken I., Buchholz H.G., Ondracek J., Siessmeier T., et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31 (2006) 1027-1035
19. Siessmeier T., Zhou Y., Buchholz H.G., Landvogt C., Vernaleken I., Piel M., et al. Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med 46 (2005) 964-972
20. Rohde G.K., Aldroubi A., and Dawant B.M. The adaptive bases algorithm for intensity-based nonrigid image registration. IEEE Trans Med Imaging 22 (2003) 1470-1479
21. Forman S.D., Cohen J.D., Fitzgerald M., Eddy W.F., Mintun M.A., and Noll D.C. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): Use of a cluster-size threshold. Magn Reson Med 33 (1995) 636-647
22. Ward B.D. Simultaneous inference for fMRI data (2000). http://afni.nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf Available at: http://afni.nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf.
23. 2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain. J Chem Neuroanatomy 9 (1995) 41-53
24. 2 receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 387 (2000) 179-188 2000
25. Kessler R.M., Mason N.S., Votaw J.R., DePaulis T., Clanton J.A., Ansari M.S., et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 223 (1992) 105-107
26. Gerhardt G.A., Cass W.A., Huettl P., Brock S., Zhang Z., and Gash D.M. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 817 (1999) 163-171
27. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., and Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80 (2002) 168-177
28. Cragg S.J., and Greenfield S.A. Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. Neurosci 17 (1997) 5738-5746
29. Sesack S.R., Aoki C., and Pickel V.M. Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. Neurosci 14 (1994) 88-106
30. Sun W., Ginovart N., Ko F., Seeman P., and Kapur S. In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: Differential findings with [3H] raclopride versus [3h] spiperone. Mol Pharmacol 63 (2003) 456-462
31. Narendran R., Slifstein M., Guillin O., Hwang Y., Hwang D.R., Scher E., et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+) PHNO is a D3 receptor preferring agonist in vivo. Synapse 60 (2006) 485-495
32. Gurevich E.V., and Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20 (1999) 60-80
33. Perachon S., Schwartz J.C., and Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 366 (1999) 293-300
34. Khan Z.U., Mrzljak L., Gutierrez A., delaCalle A., and Goldman-Rakic P.S. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A 23 (1998) 7731-7736